| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-N-Me-Ile-OH is classified as a protected N-methylated amino acid and does not have a specific biological receptor target. Its primary application is as a building block for introducing N-methylisoleucine residues into peptides during Fmoc SPPS. N-methylation reduces hydrogen bond donation, enhances peptide stability, and can improve permeability and reduce enzymatic degradation.
|
|---|---|
| ln Vitro |
In vitro activity for Fmoc-N-Me-Ile-OH is primarily as a peptide synthesis reagent. Amino acid derivatives have been commercially used as ergogenic supplements. Fmoc-N-Me-Ile-OH itself is not directly biologically active. Its utility is in preparing N-methylisoleucine-containing peptides for subsequent biological evaluation.
|
| ln Vivo |
In vivo activity data for Fmoc-N-Me-Ile-OH as a standalone compound is not applicable. It is a protected N-methylated amino acid building block used in research. Peptides synthesized using this building block may be evaluated in animal models. N-methylation can improve peptide stability, permeability, and reduce enzymatic degradation.
|
| Enzyme Assay |
In vitro SPPS protocols for Fmoc-N-Me-Ile-OH involve standard Fmoc chemistry. The compound is activated with coupling reagents such as HATU or HBTU and DIPEA in DMF, then coupled to resin-bound peptides. Fmoc deprotection uses 20% piperidine in DMF. The N-methyl group can slow coupling kinetics. Enantiomeric purity is ≥99.5%. Purity is ≥98% by HPLC.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Fmoc-N-Me-Ile-OH as it is a protected amino acid derivative. N-Methylisoleucine-containing peptides synthesized using this reagent can be tested in cell culture after deprotection. Peptides are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM for 24-72 hours.
|
| Animal Protocol |
Animal studies with Fmoc-N-Me-Ile-OH are not conducted directly. Peptides containing N-methylisoleucine residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-N-Me-Ile-OH as a standalone compound is not applicable. The compound has a molecular weight of 367.44 g/mol, formula C22H25NO4, and CAS number 138775-22-1. Appearance is white to slight yellow to beige powder. Solubility in DMSO is 25 mg/mL. Storage is at -20°C for powder.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for Fmoc-N-Me-Ile-OH. The compound is for research use only. Standard safety precautions should be observed. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
In this paper, Fmoc-N-Me-Ile-OH (CAS# 138775-22-1) is mentioned only as a commercially available N‑methyl amino acid building block used for the solid‑phase synthesis of N‑methylated R1 peptide derivatives [1][2][3]. No pharmacological, biological, metabolic, or toxicological data for this compound itself are presented or discussed [1][2][3].
Fmoc-N-Me-Ile-OH (CAS#: 138775-22-1) is also known as N-α-Fmoc-N-α-methyl-L-isoleucine and (2S,3S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylpentanoic acid. It is a non-natural amino acid used in peptide synthesis. It has no approved therapeutic indications. |
| Molecular Formula |
C22H25NO4
|
|---|---|
| Molecular Weight |
367.44
|
| Exact Mass |
367.178
|
| CAS # |
138775-22-1
|
| PubChem CID |
15433034
|
| Appearance |
White to off-white powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
537.3±29.0 °C at 760 mmHg
|
| Melting Point |
177-183ºC
|
| Flash Point |
278.7±24.3 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
5.44
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
514
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[H][C@@]([C@@H](C)CC)(N(C)C(=O)OCC1C2=CC=CC=C2C2=C1C=CC=C2)C(O)=O
|
| InChi Key |
IQIOLCJHRZWOLS-XOBRGWDASA-N
|
| InChi Code |
InChI=1S/C22H25NO4/c1-4-14(2)20(21(24)25)23(3)22(26)27-13-19-17-11-7-5-9-15(17)16-10-6-8-12-18(16)19/h5-12,14,19-20H,4,13H2,1-3H3,(H,24,25)/t14-,20-/m0/s1
|
| Chemical Name |
(2S,3S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylpentanoic acid
|
| Synonyms |
Fmoc-N-Me-Ile-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~68.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.80 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7215 mL | 13.6077 mL | 27.2153 mL | |
| 5 mM | 0.5443 mL | 2.7215 mL | 5.4431 mL | |
| 10 mM | 0.2722 mL | 1.3608 mL | 2.7215 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
